| Literature DB >> 35047062 |
Shashank Nigam1,2, Andrew Eichholz3, Madhu Bhattacharyya4, Vaishali Parulekar4, Pankaj Gupta Roy1.
Abstract
BACKGROUND: Breast cancers located centrally require excision of nipple-areola complex. A simple central wide excision is a safe option but results in suboptimal aesthetic outcome. An oncoplastic option involves therapeutic mammoplasty with or without areolar reconstruction, limited to moderate and large ptotic breasts. For small non-ptotic breasts, most surgeons would resort to mastectomy with/without reconstruction.Entities:
Keywords: central excision; centrally located breast cancer; chest wall perforator flap; extreme oncoplasty; partial breast reconstruction; volume replacement oncoplastic breast surgery
Year: 2021 PMID: 35047062 PMCID: PMC8723741 DOI: 10.3332/ecancer.2021.1311
Source DB: PubMed Journal: Ecancermedicalscience ISSN: 1754-6605
Figure 1.Photographs of case 2. (a): Marked sub-areolar lump with dashed markings for proposed central excision. (b): Lateral view showing the markings of CWPF with cross marked at perforator as identified using a handheld Doppler. (c): 2 weeks post-operative results showing reconstructed central defect with nipple and areolar reconstruction from skin of the flap. (d): 1 year post surgery and post radiotherapy results.
Figure 2.Photographs of case 3. (a): Approximately 6 months following a right vertical scar therapeutic mammoplasty for tumour located in the lower outer quadrant. The total tumour extent was 60 mm with DCIS close to medial margin. She completed adjuvant chemotherapy with a plan for mastectomy thereafter. As she was still keen on conserving her breasts, a central wide excision and partial breast reconstruction using CWPF were performed. (b and c): Front & lateral view of 3 weeks post-operative results showing reconstructed central defect with areolar reconstruction from skin of the flap.
Summary of cases with clinico-pathological details.
| Case 1 | Case 2 | Case 3 | Case 4 | |
|---|---|---|---|---|
| Age | 50 | 72 | 40 | 36 |
| Co-morbidity | Nil | Hypertension | Hypertension | Nil |
| Smoking | Nil | Nil | Nil | Nil |
| Breast size | 32B | 34C | 36C | 30AA |
| Presentation | Screen detected | Symptomatic (lump) | Symptomatic (lump) | Symptomatic (single duct nipple discharge) |
| Family history | Nil | Nil | Nil | Nil |
| Radiological size | Bifocal 24 and 15 mm (total extent 54*30 mm) | Unifocal (Mammogram and USS occult), MRI 26 mm) | Unifocal 35 mm | Radiologically occult |
| Pre-op. histology | Grade 2 IDC with IG DCIS | Grade 2 ILC with HG DCIS | Grade 3 IDC with HG DCIS | Epithelial cells on nipple discharge cytology |
| IHC | ER8, Her2 negative | ER8, Her2 negative | ER8, Her2 negative | ER8, Her2 negative |
| Post op. histology | Grade 2 IDC 25 and 16 mm with IG DCIS | Grade 2 ILC 26 and 8 mm with HG DCIS | Grade 3 IDC 35 mm with extensive HG DCIS, separate medial shave had more DCIS < 1 mm to final margin | Grade 1 mucinous 6 mm with HG DCIS on duct excision with margins involving DCIS, G2 mucinous 3 mm with HG DCIS on therapeutic surgery |
| Lymphovascular invasion | No | No | Yes | No |
| Sentinel node biopsy | 1/1 (macrometastasis, 6 mm, no ECS) | 1/2 (macrometastasis, 10 mm, no ECS) | 1/1 (micrometastasis, 1 mm, no ECS) | 0/1 |
| TNM classification | pT2N1a(sn) | pT2N1a(sn) | pT2N1mi(sn) | pT1bN0(sn) |
IDC, Invasive ductal carcinoma, no special type; ILC, Invasive lobular carcinoma; DCIS, Ductal carcinoma in-situ; IG, Intermediate grade; HG, High grade; ECS, Extracapsular spread; USS, Ultrasound scan; IHC, Immunohistochemistry
Summary of cases with treatment details.
| Case 1 | Case 2 | Case 3 | Case 4 | |
|---|---|---|---|---|
| Reason to excise nipple-areola complex | Nipple tethering | Sub-areolar lump | Involved medial margin on vertical scar therapeutic mammoplasty – adjacent to nipple | Incidental cancer on duct excision for nipple discharge |
| Whole tumour size (in mm) | 60 | 50 | 60 | 17 and 6 |
| Further axillary treatment | No further treatment arm of POSNOC trial | Axillary Radiotherapy | Nil | Nil |
| Specimen weight (in gm) | 145 | 82 | 170 therapeutic mammoplasty | 8.5 total duct excision |
| Specimen dimensions (ML×AP×SI) mm | 86×75×40 | 77×25×65 | 80×70×45 | 45×30×15 |
| Surgical margins | Clear | Inferior margin focally involved with DCIS: re-excised – no further malignancy | NA (No further malignancy seen on central excision) | Clear |
| Closest peripheral margin | 1 mm (superior) | > 5 mm | >5 mm (medial) | 10 mm |
| Duration of surgery (in min) | 140 | 110 | 120 | 110 |
| Adjuvant chemotherapy | Yes | No. Oncotype RS 11 (NHS PREDICT 4% for third generation) | Yes, following vertical scar therapeutic mammoplasty | No |
| Adjuvant radiotherapy | Yes (breast with boost) – POSNOC no axillary RT | Yes (breast, axilla, SCF) | Yes (breast with boost) | Yes (breast) |
| Adjuvant endocrine therapy | Yes (Anastrozole) | Yes (Anastrozole) | Yes (Tamoxifen). Declined Zoladex, aromatase inhibitor and bisphosphonate | Yes (Tamoxifen) |
| Wound complication | Nil | Nil | Nil | Nil |
| Shoulder function recovery | Complete | Complete | Complete | Complete |
| Aesthetic outcome | Very good | Excellent | Excellent (right bigger than left pre radiotherapy) | Excellent |
ML, medio-lateral; AP: antero-posterior; SI, supero-inferior; NA: not applicable; RS, recurrence score; RT, radiotherapy
Figure 3.Radiotherapy planning scan of case 3. The tumour bed clips have been identified with the assistance of the surgeon and outlined (in blue) and a 1cm margin added to create a planning target volume (in red).